Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PLEC | Q15149 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152657 | 0.89 | MAPT (0.50) | KCNH3MAPTALDH1A1GAAPOLB | |
| SCHEMBL19648756 | 0.88 | KCNH3 (0.46) | KCNH3MAPTALDH1A1GAAMEN1 | |
| SCHEMBL11507189 | 0.87 | MAPT (0.55) | KCNH3MAPTALDH1A1GAAPOLB | |
| SCHEMBL1533580 | 0.86 | KCNH3 (0.57) | KCNH3MAPTALDH1A1 | |
| SCHEMBL2064760 | 0.84 | MAPT (0.57) | KCNH3MAPTALDH1A1GAAMEN1 | |
| SCHEMBL23961126 | 0.82 | KCNH3 (0.66) | KCNH3MAPTALDH1A1 | |
| SCHEMBL11015521 | 0.82 | MAPT (0.44) | KCNH3MAPTALDH1A1GAAPOLB | |
| SCHEMBL14145331 | 0.82 | MAOA (0.43) | KCNH3MAPTALDH1A1GAAMEN1 | |
| SCHEMBL11035193 | 0.82 | MAPT (0.44) | KCNH3MAPTALDH1A1GAA | |
| SCHEMBL271536 | 0.80 | APP (0.50) | KCNH3MAPTALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | claimed |
| CN-115073311-B | Efficient preparation of N, N ′ Synthesis method of-di (2-hydroxyethyl) aniline | 河南大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-115073311-A | High-efficiency preparation of N, N ′ Synthesis method of (2-hydroxyethyl) aniline | 河南大学 | 2022-09-20 | — | — | CN | disclosed |
| WO-2020054670-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | 科研製薬株式会社 | 2020-03-19 | — | — | WO | disclosed |
| US-9657024-B2 | Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival | STATEGICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657024-B2 | Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival | STATEGICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20150307498-A1 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-10-29 | — | — | US | disclosed |
| US-20150307498-A1 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-10-29 | — | — | US | disclosed |
| US-9163027-B2 | Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival | STATEGICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-1765817-A1 | THIAZOLINONE UNSUBSTITUTED QUINOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-28 | — | — | EP | disclosed |
| US-20060052606-A1 | Factor xa Inhibitors | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| WO-2006002829-A1 | THIAZOLINONE UNSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004045-A1 | Thiazolinone unsubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
| EP-1581493-A1 | FACTOR XA INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004060872-A1 | FACTOR XA INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| US-4783457-A | NON-FORMAMIDINE OCTOPAMINE AGONIST | THE GENERAL HOSPITAL CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| US-4678775-A | P-OCTOPAMINE AGONIST, STIMULATOR OF ADENYLATE CYCLASE, ANALOG OF CYCLIC ADENOSINE MONOPHOSPHATE | GENERAL HOSPITAL CORPORATION THE | 1987-07-07 | — | — | US | disclosed |
| EP-0179881-A1 | PEST CONTROLLING AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-05-07 | — | — | EP | disclosed |
| WO-1985005038-A1 | PEST CONTROLLING AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1985-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307498-A1 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL | EPOR, THPO, MKI67 | KCNH3 4385/4885MAPT 4460/4885ALDH1A1 396/4885 |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | PDE3A, PDE5A, PDE2A | KCNH3 2897/4885MAPT 4590/4885ALDH1A1 247/4885 |
| US-20060052606-A1 | Factor xa Inhibitors | F12, F11, SERPINC1 | KCNH3 3051/4885MAPT 4807/4885ALDH1A1 3097/4885 |
| US-20060004045-A1 | Thiazolinone unsubstituted quinolines | CDK1, CDK17, CDK14 | KCNH3 3282/4885MAPT 1897/4885ALDH1A1 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.